{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:06:03Z","timestamp":1791975963920,"version":"4.4.0"},"reference-count":166,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of Parkinson's disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) has identified the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN's scientific department. In 2021, the first part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed\u2014among them neuropsychiatric symptoms, such as depression, anxiety, cognitive alteration, and psychosis\u2014as well as the possible recommended therapies and medications used to control pain, sleep disorders, and dysautonomia.<\/jats:p>","DOI":"10.1055\/s-0045-1802962","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:16:43Z","timestamp":1740442603000},"page":"001-015","source":"Crossref","is-referenced-by-count":2,"title":["Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology \u2013 non-motor symptoms"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-2911","authenticated-orcid":false,"given":"D\u00e9bora Palma","family":"Maia","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Hospital das Cl\u00ednicas, Departamento de Neurologia, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-3327","authenticated-orcid":false,"given":"Rubens Gisbert","family":"Cury","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, Centro de Dist\u00farbios do Movimento, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-2078","authenticated-orcid":false,"given":"Pedro Renato P.","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio Liban\u00eas, Bras\u00edlia DF, Brazil."},{"name":"Universidade de Bras\u00edlia, Hospital da Universidade de Bras\u00edlia, Bras\u00edlia DF, Brazil."},{"name":"Cl\u00ednica Neurol\u00f3gica, Departamento de Sa\u00fade, Congresso Nacional, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0808-0116","authenticated-orcid":false,"given":"Francisco E. C.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Cl\u00ednica M\u00e9dica\/Neurologia, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-9300","authenticated-orcid":false,"given":"Ana Paula","family":"Bertholo","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-2983","authenticated-orcid":false,"given":"Andr\u00e9 Carvalho","family":"Felicio","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1476-2105","authenticated-orcid":false,"given":"Arlete","family":"Hilbig","sequence":"additional","affiliation":[{"name":"Hospital S\u00e3o Jos\u00e9, Porto Alegre RS, Brazil."},{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-5710","authenticated-orcid":false,"given":"Bruno Lopes Santos","family":"Lobato","sequence":"additional","affiliation":[{"name":"Universidade Federal do Par\u00e1, Laborat\u00f3rio de Neuropatologia Experimental, Bel\u00e9m PA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7098-0775","authenticated-orcid":false,"given":"Eline Roz\u00e1ria F.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Neurol\u00f3gica, Departamento de Sa\u00fade, Congresso Nacional, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9380-238X","authenticated-orcid":false,"given":"Elizabeth Maria A. B.","family":"Quagliato","sequence":"additional","affiliation":[{"name":"Universidade Federal do Par\u00e1, Laborat\u00f3rio de Neuropatologia Experimental, Bel\u00e9m PA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-4595","authenticated-orcid":false,"given":"Gustavo H. C.","family":"Sousa","sequence":"additional","affiliation":[{"name":"Hospital de Base do Distrito Federal, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-5328","authenticated-orcid":false,"given":"Jacy Bezerra","family":"Parmera","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7819-4499","authenticated-orcid":false,"given":"M\u00e1rcia","family":"R\u00fabia","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-8492","authenticated-orcid":false,"given":"Marcus Vin\u00edcius Della","family":"Coletta","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Amazonas, Departamento de Neurologia, Escola Superior de Ci\u00eancias da Sa\u00fade, Manaus AM, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4312-3994","authenticated-orcid":false,"given":"Maria Sheila Guimar\u00e3es","family":"Rocha","sequence":"additional","affiliation":[{"name":"Hospital Santa Marcelina, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-2313","authenticated-orcid":false,"given":"Mariana","family":"Spitz","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-1686","authenticated-orcid":false,"given":"M\u00f4nica","family":"Haddad","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4615-7360","authenticated-orcid":false,"given":"Nina Rosa A. F.","family":"Murta","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Hospital das Cl\u00ednicas, Departamento de Neurologia, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-6990","authenticated-orcid":false,"given":"Paulo","family":"Caramelli","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Cl\u00ednica M\u00e9dica\/Neurologia, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-9807","authenticated-orcid":false,"given":"Raimundo N. D.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Unidade de Sono de Bras\u00edlia, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-1525","authenticated-orcid":false,"given":"Ricardo","family":"Nitrini","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0273-3104","authenticated-orcid":false,"given":"Roberto","family":"Prado","sequence":"additional","affiliation":[{"name":"Universidade Federal de Sergipe, Faculdade de Medicina, Aracaju SE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2709","authenticated-orcid":false,"given":"Vitor","family":"Tumas","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neurologia, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-5300","authenticated-orcid":false,"given":"Ylmar","family":"Corr\u00eaa Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Catarina, Faculdade de Medicina, Departamento de Neurologia, Florian\u00f3polis SC, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8145","authenticated-orcid":false,"given":"Roberta Arb","family":"Saba","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departamento de Neurologia, Setor de Transtornos do Movimento, S\u00e3o Paulo SP, Brazil."},{"name":"Hospital do Servidor P\u00fablico Estadual de S\u00e3o Paulo, Servi\u00e7o de Neurologia, Setor de Transtornos do Movimento, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1590\/0004-282X-ANP-2021-0282","article-title":"Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms","volume":"80","author":"R A Saba","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"12","key":"ref3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"M Emre","year":"2007","journal-title":"Mov Disord"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"I Litvan","year":"2012","journal-title":"Mov Disord"},{"issue":"06","key":"ref5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"M A Hely","year":"2008","journal-title":"Mov Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1590\/1980-5764-DN-2022-S101","article-title":"Diagnosis and management of Parkinson's disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology","volume":"16","author":"J B Parmera","year":"2022","journal-title":"Dement Neuropsychol"},{"issue":"03","key":"ref7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14656566.2020.1855105","article-title":"Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial","volume":"22","author":"H Sawada","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"M Ikeda","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"ref9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/jnnp-2018-318197","article-title":"Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years","volume":"89","author":"H Sawada","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000433524","article-title":"Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies","volume":"40","author":"E Mori","year":"2015","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000438824","article-title":"Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients","volume":"74","author":"Z Li","year":"2015","journal-title":"Eur Neurol"},{"issue":"07","key":"ref12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/mds.26138","article-title":"Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study","volume":"30","author":"E Mamikonyan","year":"2015","journal-title":"Mov Disord"},{"issue":"02","key":"ref13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-308764","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"H F Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"07","key":"ref14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2014-309562","article-title":"Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis","volume":"86","author":"G Pagano","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"03","key":"ref15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3892\/etm.2019.7111","article-title":"Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis","volume":"17","author":"Y H Meng","year":"2019","journal-title":"Exp Ther Med"},{"issue":"02","key":"ref16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13607863.2021.1972126","article-title":"Systematic review of pharmacological interventions for people with Lewy body dementia","volume":"27","author":"K E Watts","year":"2023","journal-title":"Aging Ment Health"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000486546","article-title":"A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia","volume":"45","author":"R Knight","year":"2018","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"01","key":"ref18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/gps.4217","article-title":"Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies","volume":"30","author":"K A Wesnes","year":"2015","journal-title":"Int J Geriatr Psychiatry"},{"issue":"07","key":"ref19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1474-4422(09)70125-2","article-title":"Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"D Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.26480","article-title":"Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial","volume":"31","author":"D Weintraub","year":"2016","journal-title":"Mov Disord"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1176\/appi.neuropsych.15050118","article-title":"Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia","volume":"29","author":"L L Frakey","year":"2017","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"02","key":"ref22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21810","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"J SAM Reijnders","year":"2008","journal-title":"Mov Disord"},{"issue":"16","key":"ref23","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182510e04","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"I H Richard","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1212\/01.wnl.0000342174.55729.a3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"M Menza","year":"2009","journal-title":"Neurology"},{"issue":"06","key":"ref25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/mds.22053","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"D Devos","year":"2008","journal-title":"Mov Disord"},{"issue":"02","key":"ref26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27757","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"K Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"06","key":"ref27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70110-6","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"P Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ajp.2021.102691","article-title":"The role of pramipexole in the treatment of patients with depression and Parkinson's disease: A meta-analysis of randomized controlled trials","volume":"61","author":"D Q Jiang","year":"2021","journal-title":"Asian J Psychiatr"},{"issue":"09","key":"ref29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jagp.2022.04.014","article-title":"Phenomenology of atypical anxiety disorders in Parkinson's disease: a systematic review","volume":"30","author":"N N Dissanayaka","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e068718","DOI":"10.1136\/bmj-2022-068718","article-title":"Management of psychiatric and cognitive complications in Parkinson's disease","volume":"379","author":"D Weintraub","year":"2022","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2020.09.006","article-title":"A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability","volume":"81","author":"R B Schneider","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"36","key":"ref32","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181549","article-title":"Canadian guideline for Parkinson disease","volume":"191","author":"D Grimes","year":"2019","journal-title":"CMAJ"},{"issue":"01","key":"ref33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03878.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"J J Ferreira","year":"2013","journal-title":"Eur J Neurol"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1002\/0470029439","volume-title":"Handbook of Psychiatric drugs. West Sussex","author":"J A Lieberman","year":"2006"},{"issue":"05","key":"ref35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.024722","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"P Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.genhosppsych.2024.02.008","article-title":"Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis","volume":"87","author":"M Srisurapanont","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"ref37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(99)01740-4","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"issue":"05","key":"ref39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0006-3223(02)01423-9","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"A Breier","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1176\/jnp.7.4.471","article-title":"Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease","volume":"7","author":"R C Chacko","year":"1995","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"01","key":"ref41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135:AID-MDS1021>3.0.CO;2-X","article-title":"Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial","volume":"16","author":"S A Factor","year":"2001","journal-title":"Mov Disord"},{"issue":"05","key":"ref42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"E C Wolters","year":"1990","journal-title":"Neurology"},{"issue":"04","key":"ref43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mds.10242","article-title":"The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia","volume":"17","author":"S Reddy","year":"2002","journal-title":"Mov Disord"},{"issue":"05","key":"ref44","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.10482","article-title":"Long-term outcome of quetiapine use for psychosis among Parkinsonian patients","volume":"18","author":"H H Fernandez","year":"2003","journal-title":"Mov Disord"},{"issue":"01","key":"ref45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/mds.10632","article-title":"Quetiapine improves psychotic symptoms and cognition in Parkinson's disease","volume":"19","author":"J L Juncos","year":"2004","journal-title":"Mov Disord"},{"issue":"02","key":"ref46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00415-005-0057-0","article-title":"The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview","volume":"253","author":"T Prohorov","year":"2006","journal-title":"J Neurol"},{"issue":"08","key":"ref47","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/mds.20694","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"W G Ondo","year":"2005","journal-title":"Mov Disord"},{"issue":"03","key":"ref48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.21192","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration","volume":"22","author":"J M Rabey","year":"2007","journal-title":"Mov Disord"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"L Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"D Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"06","key":"ref51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"C G Goetz","year":"2000","journal-title":"Neurology"},{"issue":"05","key":"ref52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/mds.10171","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"W G Ondo","year":"2002","journal-title":"Mov Disord"},{"issue":"02","key":"ref53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/1531-8257(200003)15:2<301:AID-MDS1026>3.0.CO;2-J","article-title":"Risperidone treatment of drug-related psychosis in patients with parkinsonism","volume":"15","author":"N A Leopold","year":"2000","journal-title":"Mov Disord"},{"issue":"06","key":"ref54","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230:AID-MDS1032>3.0.CO;2-0","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial","volume":"15","author":"E Mohr","year":"2000","journal-title":"Mov Disord"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mds.29700","article-title":"Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus","volume":"39","author":"I Debove","year":"2024","journal-title":"Mov Disord"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FBP.0b013e32832b89d2","article-title":"Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease","volume":"20","author":"S Fenu","year":"2009","journal-title":"Behav Pharmacol"},{"issue":"05","key":"ref57","first-page":"316","article-title":"[Pathological gambling associated with pramipexole use in Parkinson's disease]","volume":"43","author":"J Lester","year":"2006","journal-title":"Rev Neurol"},{"issue":"03","key":"ref58","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22053","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"A Thomas","year":"2010","journal-title":"Ann Neurol"},{"issue":"11","key":"ref59","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.5664\/jcsm.3172","article-title":"Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities","volume":"9","author":"S Chung","year":"2013","journal-title":"J Clin Sleep Med"},{"issue":"S 01","key":"ref60","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s004150050209","article-title":"Sleep disorders in Parkinson's disease","volume":"245","author":"F Stocchi","year":"1998","journal-title":"J Neurol"},{"issue":"10","key":"ref61","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1007\/s10072-022-05906-z","article-title":"Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial","volume":"43","author":"F Hadi","year":"2022","journal-title":"Neurol Sci"},{"issue":"11","key":"ref62","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/mds.23144","article-title":"Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo","volume":"25","author":"M Menza","year":"2010","journal-title":"Mov Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.sleep.2015.11.017","article-title":"Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study","volume":"21","author":"M Pierantozzi","year":"2016","journal-title":"Sleep Med"},{"issue":"01","key":"ref64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23339","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"C Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"issue":"05","key":"ref65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.002","article-title":"Melatonin for sleep disturbances in Parkinson's disease","volume":"6","author":"G A Dowling","year":"2005","journal-title":"Sleep Med"},{"issue":"04","key":"ref66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00415-006-0467-z","article-title":"Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study","volume":"254","author":"C AM Medeiros","year":"2007","journal-title":"J Neurol"},{"issue":"04","key":"ref67","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ene.13587","article-title":"Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial","volume":"25","author":"W Schrempf","year":"2018","journal-title":"Eur J Neurol"},{"issue":"06","key":"ref68","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/JCP.0000000000000362","article-title":"Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction","volume":"35","author":"A Avila","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"01","key":"ref69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40035-023-00251-x","article-title":"Circadian disruption and sleep disorders in neurodegeneration","volume":"12","author":"Y Shen","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"08","key":"ref70","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4103\/0366-6999.228342","article-title":"Excessive daytime sleepiness in Parkinson's disease: clinical implications and management","volume":"131","author":"Y Shen","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"03","key":"ref71","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11538130-000000000-00000","article-title":"Excessive daytime sleepiness in patients with Parkinson's disease","volume":"25","author":"B Knie","year":"2011","journal-title":"CNS Drugs"},{"issue":"08","key":"ref72","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1212\/WNL.57.8.1392","article-title":"Daytime sleepiness and other sleep disorders in Parkinson's disease","volume":"57","author":"W G Ondo","year":"2001","journal-title":"Neurology"},{"issue":"04","key":"ref73","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/1531-8257(200007)15:4<658:AID-MDS1012>3.0.CO;2-B","article-title":"Pramipexole-induced somnolence and episodes of daytime sleep","volume":"15","author":"R A Hauser","year":"2000","journal-title":"Mov Disord"},{"issue":"06","key":"ref74","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/mds.10564","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease","volume":"18","author":"S Paus","year":"2003","journal-title":"Mov Disord"},{"issue":"08","key":"ref75","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/sleep\/25.8.905","article-title":"Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial","volume":"25","author":"B H\u00f6gl","year":"2002","journal-title":"Sleep"},{"issue":"12","key":"ref76","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/jnnp.2004.056526","article-title":"Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial","volume":"76","author":"W G Ondo","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"06","key":"ref77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5664\/jcsm.26760","article-title":"Evaluation of the safety of modafinil for treatment of excessive sleepiness","volume":"3","author":"T Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"issue":"14","key":"ref78","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/mds.21599","article-title":"Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial","volume":"22","author":"D A Mendon\u00e7a","year":"2007","journal-title":"Mov Disord"},{"issue":"05","key":"ref79","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/jnnp.2006.103657","article-title":"Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease","volume":"78","author":"D Devos","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2016.04.011","article-title":"Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis","volume":"27","author":"T M Rodrigues","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"01","key":"ref81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-018-0019-3","article-title":"REM sleep behaviour disorder","volume":"4","author":"Y Dauvilliers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"03","key":"ref82","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0002-9343(96)00019-1","article-title":"Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults","volume":"100","author":"C H Schenck","year":"1996","journal-title":"Am J Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.sleep.2015.12.014","article-title":"A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder","volume":"21","author":"S X Li","year":"2016","journal-title":"Sleep Med"},{"issue":"04","key":"ref84","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2869.2010.00833.x","article-title":"A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder","volume":"19","author":"D Kunz","year":"2010","journal-title":"J Sleep Res"},{"issue":"08","key":"ref85","doi-asserted-by":"publisher","first-page":"zsad103","DOI":"10.1093\/sleep\/zsad103","article-title":"Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder","volume":"46","author":"E H During","year":"2023","journal-title":"Sleep"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jocn.2021.07.022","article-title":"Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study","volume":"91","author":"M Plastino","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2169\/internalmedicine.55.5464","article-title":"Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial","volume":"55","author":"K Kashihara","year":"2016","journal-title":"Intern Med"},{"issue":"07","key":"ref88","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.28550","article-title":"Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder","volume":"36","author":"C MO de Almeida","year":"2021","journal-title":"Mov Disord"},{"issue":"10","key":"ref89","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/01.WNL.0000091009.63992.40","article-title":"The effects of pramipexole in REM sleep behavior disorder","volume":"61","author":"M L Fantini","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"ref90","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.5664\/jcsm.6200","article-title":"Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease","volume":"12","author":"Y Wang","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"06","key":"ref91","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1212\/WNL.55.6.870","article-title":"Treatment of REM sleep behavior disorder with donepezil: a report of three cases","volume":"55","author":"J M Ringman","year":"2000","journal-title":"Neurology"},{"issue":"01","key":"ref92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/sleep\/16.1.33","article-title":"Carbamazepine in REM sleep behavior disorder","volume":"16","author":"C R Bamford","year":"1993","journal-title":"Sleep"},{"issue":"04","key":"ref93","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/mds.24925","article-title":"Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease","volume":"27","author":"R Di Giacopo","year":"2012","journal-title":"Mov Disord"},{"issue":"08","key":"ref94","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance","volume":"15","author":"R P Allen","year":"2014","journal-title":"Sleep Med"},{"issue":"07","key":"ref95","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.27360","article-title":"Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)\u00a7","volume":"33","author":"J Winkelmann","year":"2018","journal-title":"Mov Disord"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.sleep.2017.11.019","article-title":"Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report","volume":"41","author":"R P Allen","year":"2018","journal-title":"Sleep Med"},{"issue":"04","key":"ref97","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.sleep.2010.06.005","article-title":"Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome","volume":"12","author":"B H\u00f6gl","year":"2011","journal-title":"Sleep Med"},{"issue":"09","key":"ref98","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/mds.21047","article-title":"Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome","volume":"21","author":"C Trenkwalder","year":"2006","journal-title":"Mov Disord"},{"issue":"08","key":"ref99","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1474-4422(11)70123-2","article-title":"Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study","volume":"10","author":"W Oertel","year":"2011","journal-title":"Lancet Neurol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2015.12.010","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"21","author":"D Garcia-Borreguero","year":"2016","journal-title":"Sleep Med"},{"issue":"07","key":"ref101","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1313131","article-title":"Comparison of pregabalin with pramipexole for restless legs syndrome","volume":"370","author":"R P Allen","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"ref102","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/01.WNL.0000037229.35129.88","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"D Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"issue":"02","key":"ref103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.12.019","article-title":"Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients","volume":"36","author":"Y Inoue","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"01","key":"ref104","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1185\/03007995.2012.751808","article-title":"Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study","volume":"29","author":"Y Inoue","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"04","key":"ref105","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","article-title":"Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo","volume":"16","author":"A S Walters","year":"1993","journal-title":"Sleep"},{"issue":"02","key":"ref106","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/can.2023.0042","article-title":"The Effect of Cannabidiol for Restless Legs Syndrome\/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2\/3 Clinical Trial","volume":"8","author":"C MO de Almeida","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"issue":"01","key":"ref107","doi-asserted-by":"publisher","first-page":"CD007834","DOI":"10.1002\/14651858.CD007834.pub3","article-title":"Iron for the treatment of restless legs syndrome","volume":"1","author":"L M Trotti","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"751643","DOI":"10.3389\/fnins.2021.751643","article-title":"The Efficacy and Safety of Pharmacological Treatments for Restless Legs Syndrome: Systemic Review and Network Meta-Analysis","volume":"15","author":"X Zhou","year":"2021","journal-title":"Front Neurosci"},{"issue":"09","key":"ref109","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.sleep.2011.04.014","article-title":"Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial","volume":"12","author":"R P Allen","year":"2011","journal-title":"Sleep Med"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"105790","DOI":"10.1016\/j.parkreldis.2023.105790","article-title":"Obstructive sleep apnea in Parkinson's disease: A prevalent, clinically relevant and treatable feature","volume":"115","author":"Q Yu","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"05","key":"ref111","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10072-020-04338-0","article-title":"The relationship between obstructive sleep apnea and Parkinson's disease: a systematic review and meta-analysis","volume":"41","author":"A P Sun","year":"2020","journal-title":"Neurol Sci"},{"issue":"01","key":"ref112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11325-015-1235-1","article-title":"Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime","volume":"20","author":"P Gros","year":"2016","journal-title":"Sleep Breath"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.11138\/FNeur\/2017.32.3.137","article-title":"Obstructive sleep apnea syndrome in Parkinson's disease and other parkinsonisms","volume":"32","author":"F Crosta","year":"2017","journal-title":"Funct Neurol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sleep.2015.12.010","article-title":"Obstructive Sleep Apnea and Cognition in Parkinson's disease","volume":"21","author":"A L Harmell","year":"2016","journal-title":"Sleep Med"},{"issue":"05","key":"ref115","doi-asserted-by":"publisher","first-page":"819","DOI":"10.5664\/jcsm.7196","article-title":"Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease","volume":"14","author":"M Kaminska","year":"2018","journal-title":"J Clin Sleep Med"},{"issue":"01","key":"ref116","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5665\/sleep.3354","article-title":"Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea","volume":"37","author":"A B Neikrug","year":"2014","journal-title":"Sleep"},{"issue":"03","key":"ref117","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002512-200926030-00002","article-title":"Physical and mental fatigue in Parkinson's disease: epidemiology, pathophysiology and treatment","volume":"26","author":"J S Lou","year":"2009","journal-title":"Drugs Aging"},{"issue":"13","key":"ref118","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/mds.26372","article-title":"Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease","volume":"30","author":"T T Lim","year":"2015","journal-title":"Mov Disord"},{"issue":"07","key":"ref119","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/mds.26652","article-title":"Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease","volume":"31","author":"B M Kluger","year":"2016","journal-title":"Mov Disord"},{"issue":"04","key":"ref120","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/mds.24965","article-title":"Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool","volume":"27","author":"M PG Broen","year":"2012","journal-title":"Mov Disord"},{"issue":"03","key":"ref121","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737175.2021.1865732","article-title":"Non-motor complications in late stage Parkinson's disease: recognition, management and unmet needs","volume":"21","author":"K Rukavina","year":"2021","journal-title":"Expert Rev Neurother"},{"issue":"04","key":"ref122","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/wnf.0b013e3180340319","article-title":"The effect of duloxetine on primary pain symptoms in Parkinson disease","volume":"30","author":"R Djaldetti","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"116833","DOI":"10.1016\/j.jns.2020.116833","article-title":"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease","volume":"414","author":"H Iwaki","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2377-14-42","article-title":"Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study","volume":"14","author":"J Kassubek","year":"2014","journal-title":"BMC Neurol"},{"issue":"07","key":"ref125","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain","volume":"56","author":"O Rascol","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"02","key":"ref126","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25748","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"R Borgohain","year":"2014","journal-title":"Mov Disord"},{"key":"ref127","first-page":"S308","article-title":"SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's disease (poster)","volume":"25","author":"A Schapira","year":"2010","journal-title":"Mov Disord"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JPD-160911","article-title":"Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis","volume":"7","author":"C Cattaneo","year":"2017","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"ref129","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00275-9","article-title":"Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial","volume":"14","author":"C Trenkwalder","year":"2015","journal-title":"Lancet Neurol"},{"issue":"09","key":"ref130","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/mds.29878","article-title":"Oxycodone or Higher Dose of Levodopa for the treatment os parkinsonian Central Pain: OXYDOPA trial","volume":"39","author":"C Brefel-Courbon","year":"2024","journal-title":"Mov Disord"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"L Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"06","key":"ref132","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","article-title":"Pregabalin-induced parkinsonism: a case report","volume":"32","author":"S Perez Lloret","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3389\/fneur.2019.01114","article-title":"Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease","volume":"10","author":"S W Yu","year":"2019","journal-title":"Front Neurol"},{"issue":"07","key":"ref134","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mdc3.13352","article-title":"A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease","volume":"10","author":"D G Di Luca","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"07","key":"ref135","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/j.1532-2149.2019.00977.x","article-title":"Exercise-induced hypoalgesia is present in people with Parkinson's disease: Two observational cross-sectional studies","volume":"23","author":"V Nguy","year":"2019","journal-title":"Eur J Pain"},{"issue":"05","key":"ref136","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1055\/s-0040-1703571","article-title":"Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges","volume":"40","author":"J A Palma","year":"2020","journal-title":"Semin Neurol"},{"issue":"08","key":"ref137","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00415-017-8532-5","article-title":"The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension","volume":"264","author":"C H Gibbons","year":"2017","journal-title":"J Neurol"},{"issue":"04","key":"ref138","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10286-016-0370-1","article-title":"Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study","volume":"26","author":"W Smith","year":"2016","journal-title":"Clin Auton Res"},{"issue":"04","key":"ref139","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/WNL.0000000000000673","article-title":"Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial","volume":"83","author":"H Kaufmann","year":"2014","journal-title":"Neurology"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"120008","DOI":"10.1016\/j.jns.2021.120008","article-title":"Consensus on the treatment of dysphagia in Parkinson's disease","volume":"430","author":"A Schindler","year":"2021","journal-title":"J Neurol Sci"},{"issue":"01","key":"ref141","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1044\/2021_AJSLP-20-00256","article-title":"Effectiveness of Interventions for Dysphagia in Parkinson Disease: A Systematic Review","volume":"31","author":"P Gandhi","year":"2022","journal-title":"Am J Speech Lang Pathol"},{"issue":"11","key":"ref142","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/toxins12110691","article-title":"Sialorrhea in Parkinson's disease","volume":"12","author":"J Isaacson","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"03","key":"ref143","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/mds.27379","article-title":"Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies","volume":"33","author":"J A Palma","year":"2018","journal-title":"Mov Disord"},{"issue":"03","key":"ref144","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40263-019-00612-8","article-title":"Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis","volume":"33","author":"S Y Chen","year":"2019","journal-title":"CNS Drugs"},{"issue":"05","key":"ref145","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.007","article-title":"Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease","volume":"21","author":"T A Zesiewicz","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"105822","DOI":"10.1016\/j.parkreldis.2023.105822","article-title":"Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease","volume":"115","author":"D S Abraham","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"03","key":"ref147","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.juro.2011.04.017","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"A Giannantoni","year":"2011","journal-title":"J Urol"},{"issue":"03","key":"ref148","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/mdc3.13469","article-title":"The profound impact of gastrointestinal stasis on levodopa response in Parkinson's disease","volume":"9","author":"L J Williams","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"01","key":"ref149","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-022-00256-5","article-title":"Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management","volume":"8","author":"T Warnecke","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"09","key":"ref150","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mds.21453","article-title":"Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study","volume":"22","author":"R Zangaglia","year":"2007","journal-title":"Mov Disord"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41531-018-0042-8","article-title":"Management of constipation in patients with Parkinson's disease","volume":"4","author":"A J Pedrosa Carrasco","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"issue":"21","key":"ref152","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e318256f20f","article-title":"Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease","volume":"78","author":"W G Ondo","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"ref153","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003103","article-title":"Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT","volume":"87","author":"M Barichella","year":"2016","journal-title":"Neurology"},{"issue":"05","key":"ref154","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1212\/WNL.0000000000011780","article-title":"Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study","volume":"96","author":"A H Tan","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"ref155","doi-asserted-by":"crossref","first-page":"e0244680","DOI":"10.1371\/journal.pone.0244680","article-title":"Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial","volume":"15","author":"A Ibrahim","year":"2020","journal-title":"PLoS One"},{"key":"ref156","first-page":"4842090","article-title":"Abdominal Massage for the Relief of Constipation in People with Parkinson's: A Qualitative Study","volume":"2016","author":"D McClurg","year":"2016","journal-title":"Parkinsons Dis"},{"issue":"02","key":"ref157","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mdc3.12577","article-title":"Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism","volume":"5","author":"M E Freitas","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"ref158","first-page":"35","article-title":"The effects of lactulose on constipation in patients with Parkinson's disease: An exploratory pilot study","volume":"10","author":"K Si","year":"2024","journal-title":"Neurol Sci"},{"issue":"07","key":"ref159","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/brainsci11070831","article-title":"Gastroparesis in Parkinson disease: pathophysiology and clinical management","volume":"11","author":"H Soliman","year":"2021","journal-title":"Brain Sci"},{"issue":"03","key":"ref160","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/jcm10030493","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"10","author":"C Skj\u00e6rb\u00e6k","year":"2021","journal-title":"J Clin Med"},{"issue":"06","key":"ref161","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/mds.870120611","article-title":"Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease","volume":"12","author":"I Soykan","year":"1997","journal-title":"Mov Disord"},{"issue":"10","key":"ref162","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.jsxm.2020.06.007","article-title":"Sexual dysfunction in Parkinson disease: a multicenter Italian cross-sectional study on a still overlooked problem","volume":"17","author":"L Raciti","year":"2020","journal-title":"J Sex Med"},{"issue":"04","key":"ref163","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s13311-020-00895-6","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"17","author":"R F Pfeiffer","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mdc3.12561","article-title":"The Role of Sex Therapy in the Management of Patients with Parkinson's Disease","volume":"5","author":"G Bronner","year":"2017","journal-title":"Mov Disord Clin Pract"},{"issue":"03","key":"ref165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mdc3.12456","article-title":"Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease","volume":"4","author":"B A Bernard","year":"2016","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"ref166","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1001\/archneur.59.11.1750","article-title":"Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease","volume":"59","author":"M S Okun","year":"2002","journal-title":"Arch Neurol"},{"issue":"01","key":"ref167","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cger.2019.08.007","article-title":"Management of urologic and sexual dysfunction in Parkinson disease","volume":"36","author":"J Margolesky","year":"2020","journal-title":"Clin Geriatr Med"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1802962.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:17:05Z","timestamp":1740442625000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1802962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":166,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["s00451802962"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1802962","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}